FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120244688> ?p ?o ?g. }

• W3120244688 endingPage "261" @default.
• W3120244688 startingPage "255" @default.
• W3120244688 abstract "There are limited data on the risks and benefits of using andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F-PCC) to reverse factor Xa inhibitors (FXi) associated intracranial hemorrhage (ICH). We sought to describe our experience with AA or 4F-PCC in patients with oral FXi-related traumatic and spontaneous ICH. We conducted a retrospective review of consecutive adult patients with FXi-related ICH who received AA or 4F-PCC. FXi-related ICH cases included traumatic and spontaneous intracranial hemorrhages. Our primary analysis evaluated ICH stability on head computed tomography scan (CT), defined as a similar amount of blood from the initial scan at the onset of ICH to subsequent scans, at 6-h and 24-h post-administration of AA or 4F-PCC. For the subset of spontaneous intraparenchymal hemorrhages, volume was measured at 6-h and 24-h post-reversal. In secondary analyses, we evaluated good functional outcome at discharge, defined as a Modified Rankin Score of less than 3, and the incidence of thrombotic events after AA or 4F-PCC adminstration, during hospitalization. A total of 44 patients (16 traumatic and 28 spontaneous ICH) with median age of 79 years [72–86], 36% females, with a FXi-related ICH, were included in this study. The majority of spontaneous ICHs were intraparenchymal 19 (68%). Twenty-eight patients (64%) received AA and 16 patients (36%) received 4F-PCC. There was no difference between AA and 4F-PCC in terms of CT stability at 6 h (21 [78%] vs 10 [71%], p = 0.71) and 24 h (15 [88%] vs 6 [60%], p = 0.15). In a subgroup of patients with spontaneous intraparenchymal hemorrhage, there was no difference in the degree of achieved hemostasis based on hematoma volume between AA and 4F-PCC at 6 h (9.3 mL [6.9–26.4] vs 10 mL [9.4–22.1], adjusted p = 0. 997) and 24-h (9.2 mL [6.1–18.8] vs 9.9 [9.4–21.1], adjusted p = 1). The number of patients with good outcome based on mRS on discharge were 10 (36%) and 6 (38%) in the AA and 4F-PCC groups, respectively (adjusted p = 0.81). The incidence of thromboembolic events was similar in the AA and 4F-PCC groups (2 [7%] vs 0, p = 0.53). In this limited sample of patients, we found no difference in neuroimaging stability, functional outcome and thrombotic events when comparing AA and 4F-PCC in patients with FXi-related ICH. Since our analysis is likely underpowered, a multi-center collaborative network devoted to this question is warranted." @default.
• W3120244688 created "2021-01-18" @default.
• W3120244688 creator A5042694519 @default.
• W3120244688 creator A5045293964 @default.
• W3120244688 creator A5053098139 @default.
• W3120244688 creator A5057773817 @default.
• W3120244688 creator A5067289488 @default.
• W3120244688 creator A5076569070 @default.
• W3120244688 creator A5082783439 @default.
• W3120244688 creator A5087190024 @default.
• W3120244688 date "2021-01-06" @default.
• W3120244688 modified "2023-10-17" @default.
• W3120244688 title "Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage" @default.
• W3120244688 cites W2007301755 @default.
• W3120244688 cites W2097854437 @default.
• W3120244688 cites W2115787552 @default.
• W3120244688 cites W2134070683 @default.
• W3120244688 cites W2162508946 @default.
• W3120244688 cites W2166402206 @default.
• W3120244688 cites W2174386486 @default.
• W3120244688 cites W2888082174 @default.
• W3120244688 cites W2902233584 @default.
• W3120244688 cites W2914381505 @default.
• W3120244688 cites W2932976565 @default.
• W3120244688 cites W2946701789 @default.
• W3120244688 cites W2984950032 @default.
• W3120244688 cites W2992777502 @default.
• W3120244688 cites W3014120696 @default.
• W3120244688 cites W3014238593 @default.
• W3120244688 cites W3015446292 @default.
• W3120244688 cites W3042321076 @default.
• W3120244688 cites W3171831654 @default.
• W3120244688 doi "https://doi.org/10.1007/s12028-020-01161-5" @default.
• W3120244688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33403588" @default.
• W3120244688 hasPublicationYear "2021" @default.
• W3120244688 type Work @default.
• W3120244688 sameAs 3120244688 @default.
• W3120244688 citedByCount "40" @default.
• W3120244688 countsByYear W31202446882021 @default.
• W3120244688 countsByYear W31202446882022 @default.
• W3120244688 countsByYear W31202446882023 @default.
• W3120244688 crossrefType "journal-article" @default.
• W3120244688 hasAuthorship W3120244688A5042694519 @default.
• W3120244688 hasAuthorship W3120244688A5045293964 @default.
• W3120244688 hasAuthorship W3120244688A5053098139 @default.
• W3120244688 hasAuthorship W3120244688A5057773817 @default.
• W3120244688 hasAuthorship W3120244688A5067289488 @default.
• W3120244688 hasAuthorship W3120244688A5076569070 @default.
• W3120244688 hasAuthorship W3120244688A5082783439 @default.
• W3120244688 hasAuthorship W3120244688A5087190024 @default.
• W3120244688 hasBestOaLocation W31202446882 @default.
• W3120244688 hasConcept C118552586 @default.
• W3120244688 hasConcept C120665830 @default.
• W3120244688 hasConcept C121332964 @default.
• W3120244688 hasConcept C126322002 @default.
• W3120244688 hasConcept C16568411 @default.
• W3120244688 hasConcept C2776301958 @default.
• W3120244688 hasConcept C2777091921 @default.
• W3120244688 hasConcept C2777736543 @default.
• W3120244688 hasConcept C2779161974 @default.
• W3120244688 hasConcept C2779889316 @default.
• W3120244688 hasConcept C2780819430 @default.
• W3120244688 hasConcept C2780931571 @default.
• W3120244688 hasConcept C2910744652 @default.
• W3120244688 hasConcept C3020199598 @default.
• W3120244688 hasConcept C42219234 @default.
• W3120244688 hasConcept C541997718 @default.
• W3120244688 hasConcept C61511704 @default.
• W3120244688 hasConcept C71924100 @default.
• W3120244688 hasConceptScore W3120244688C118552586 @default.
• W3120244688 hasConceptScore W3120244688C120665830 @default.
• W3120244688 hasConceptScore W3120244688C121332964 @default.
• W3120244688 hasConceptScore W3120244688C126322002 @default.
• W3120244688 hasConceptScore W3120244688C16568411 @default.
• W3120244688 hasConceptScore W3120244688C2776301958 @default.
• W3120244688 hasConceptScore W3120244688C2777091921 @default.
• W3120244688 hasConceptScore W3120244688C2777736543 @default.
• W3120244688 hasConceptScore W3120244688C2779161974 @default.
• W3120244688 hasConceptScore W3120244688C2779889316 @default.
• W3120244688 hasConceptScore W3120244688C2780819430 @default.
• W3120244688 hasConceptScore W3120244688C2780931571 @default.
• W3120244688 hasConceptScore W3120244688C2910744652 @default.
• W3120244688 hasConceptScore W3120244688C3020199598 @default.
• W3120244688 hasConceptScore W3120244688C42219234 @default.
• W3120244688 hasConceptScore W3120244688C541997718 @default.
• W3120244688 hasConceptScore W3120244688C61511704 @default.
• W3120244688 hasConceptScore W3120244688C71924100 @default.
• W3120244688 hasIssue "1" @default.
• W3120244688 hasLocation W31202446881 @default.
• W3120244688 hasLocation W31202446882 @default.
• W3120244688 hasLocation W31202446883 @default.
• W3120244688 hasOpenAccess W3120244688 @default.
• W3120244688 hasPrimaryLocation W31202446881 @default.
• W3120244688 hasRelatedWork W1972047311 @default.
• W3120244688 hasRelatedWork W2025797576 @default.
• W3120244688 hasRelatedWork W2552763504 @default.
• W3120244688 hasRelatedWork W2557197638 @default.
• W3120244688 hasRelatedWork W2943559329 @default.

• next